Navigation Links
Second Phase III Study of Avastin in 1st Line Metastatic Breast Cancer Meets its Primary Endpoint
Date:2/12/2008

- Results of This Trial Further Confirm the Benefit Avastin Brings to

Patients With Breast Cancer.

BASEL, Switzerland, Feb. 13 /PRNewswire/ -- Roche announced today that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination with docetaxel chemotherapy compared to docetaxel alone, met its primary endpoint of improving the time patients live without their disease advancing.

The findings come from the first analysis of the phase III "Avastin and Docetaxel" ("AVADO", BO17708) study which investigated the addition of docetaxel to Avastin administered either at 7.5 or 15 mg/kg every 3 weeks. Both doses of Avastin in combination with chemotherapy showed statistically significant improvements in the time patients live without their disease advancing, as measured by progression-free survival, compared to chemotherapy alone. The study was not designed to compare the two Avastin-containing arms.

No new safety signals related to Avastin were observed in the trial.

Dr David Miles, medical oncologist, Mount Vernon Hospital, UK and principal investigator of AVADO, welcomed the news: "Each year more than one million women are diagnosed with breast cancer leading to over 400,000 deaths globally. This study confirms Avastin's effect of prolonging the time in which patients live without their disease getting worse in combination with a widely used chemotherapy partner -- this time gained is very precious."

The efficacy and safety data of AVADO will be presented at an upcoming medical meeting.

This second positive phase III trial follows the recently published landmark E2100 study, which formed the basis of European Commission approval of Avastin in combination with paclitaxel for the 1st line treatment of metastatic breast cancer in March 2007. Study E2100 showed that the addition of Avastin to paclitaxel resulted in a doubling of progression-free survival compared to paclitaxel alone.

About the BO17708 study

BO17708 is an international phase III trial which randomized 736 patients who did not receive previous chemotherapy for their metastatic breast cancer to one of three groups;

-- Avastin 7.5 mg/kg every 3 weeks in combination with docetaxel

-- Avastin 15 mg/kg every 3 weeks in combination with docetaxel

-- docetaxel + placebo as control arm

The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms compared to the control arm. Secondary endpoints for the study included overall survival, response rate, duration of response, quality of life, safety and tolerability.

About Avastin

Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal, breast, lung, and kidney cancer:

-- February 2004 (US) and January 2005 (EU) -- first-line treatment in

patients with metastatic colorectal cancer (CRC).

-- June 2006 (US) -- second-line treatment in patients with metastatic

CRC.

-- October 2006 (US) -- first-line treatment in patients with advanced

non-small cell lung cancer (NSCLC).

-- March 2007 (EU) -- first-line treatment in patients with metastatic

breast cancer.

-- April 2007 (Japan) -- treatment in patients with recurrent or advanced

CRC.

-- August 2007 (EU) -- first-line treatment in patients with advanced

NSCLC.

-- December 2007 (EU) -- first-line treatment in patients with advanced

RCC.

-- January 2008 (EU) -- first and later-line treatment in patients with

metastatic CRC in combination with any chemotherapy.

All trademarks used or mentioned in this release are legally protected.

Additional information

To access video clips about Avastin, in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com.


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Second Thoughts about Fluoride, Reports Scientific American
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Immtech Reports Fiscal Second Quarter 2008 Results
9. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
10. Rcadias COR Analyzer Family of Products Receives Second FDA Clearance
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):